MTOR and tuberous sclerosis: Solid evidence exists for mTOR inhibitors, such as everolimus, which have demonstrated consistent efficacy in the treatment of SEGAs in patients with tuberous sclerosis complex, supported by early phase II data [94], the pivotal phase III EXIST-1 trial [95], and phase III evidence from the EXIST-3 study demonstrating substantial seizure reduction [96].